ASCVD needs innovation

By Xcenda

Atherosclerotic cardiovascular disease (ASCVD) is insidiously common—it is the leading cause of death in the US and the underlying cause in about 50% of all deaths in Western societies. It is known more commonly by its myriad and negative outcomes, including myocardial infarction (MI), angina, stroke/transient ischemic attack, peripheral artery disease, heart failure, and atrial fibrillation, than by the collective term ASCVD.

Unfortunately, there is no magic bullet to improve outcomes. Many of the first-line prescription drugs to lower risk factors for ASCVD are low-cost generics and thus have broad coverage among payers. Despite the easy access to high-value drugs, there are persistent gaps in adherence.

Other patients with adverse outcomes simply do not respond—or respond well—to the available therapies, despite fully complying with their physicians’ instruction. This biologic basis for a less-than-average response shows the need and opportunity for continued innovation to develop treatments for the spectrum of people with ASCVD.

Read Xcenda’s white paper for our analysis about the need for continued innovation to treat ASCVD. And view our on-demand webinar below that was presented live on November 2, 2021.

abstract waves

White paper

Undervaluing diagnosis and treatment of ASCVD

Recorded on November 2, 2021

On-demand webinar

Xcenda's Jennifer Snow moderated a webinar on November 2, 2021 to discuss the need for innovation to treat ASCVD and the barriers limiting more—and better—approaches to the disease. Our panelists included Yesenia Araujo, a WomenHeart Champion, and Scott Shields, Associate Director, Reimbursement and Policy Insights at Xcenda.